Stempoint Capital News Today

Shares of CARGO Therapeutics, Inc. (NASDAQ:CRGX – Get Free Report) fell 9.4% on Tuesday . The company traded as low as $18.52 and last traded at $18.90. 48,484 shares were traded during trading, a decline of 80% from the average session volume of 242,179 shares. The stock had previously closed at $20.86. Analyst Upgrades and […]

Truist Financial reaffirmed their buy rating on shares of CARGO Therapeutics (NASDAQ:CRGX – Free Report) in a research note released on Thursday morning, Benzinga reports. The firm currently has a $32.00 target price on the stock, down from their prior target price of $34.00. Separately, Jefferies Financial Group boosted their price objective on CARGO Therapeutics […]

Rising star: Michelle Ross on Crinetics Pharmaceuticals Like in many other years, this years Sohn New York conference kicked off with several "Next Wave" speakers,

NEW YORK, April 05, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative thera...

NEW YORK and WALTHAM, Mass., Jan. 22, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (“Dianthus” or the “Company”) (NASDAQ: DNTH), a clini...

AC Immune Announces Pricing of Underwritten Offering of Common Shares Lausanne, Switzerland, December 15, 2023 – AC Immune SA (Nasdaq: ACIU) (the...

AC Immune Announces Pricing of Underwritten Offering of Common Shares Lausanne, Switzerland, December 15, 2023 – AC Immune SA (Nasdaq: ACIU) (the “Company” or “AC Immune”), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that it has priced an underwritten offering of 14.3 million of its common shares at a price of USD 3.50 per share. The Company expects the gross proceeds from the offering...

Tourmaline will be focused on advancing TOUR006, its differentiated anti-IL-6 antibody, to treat thyroid eye disease (TED), atherosclerotic cardiovascular...

Merger to create Nasdaq-listed, late-stage clinical biotechnology company focused on developing Tourmaline's anti-IL-6 antibody (TOUR006) in thyroid eye disease (TED) and atherosclerotic cardiovascular disease (ASCVD)

These ten up-and-comers will be honored at Institutional Investor’s Hedge Fund Industry Awards on May 11.